Armed Forces: Mefloquine

Ministry of Defence written question – answered at on 22 July 2019.

Alert me about debates like this

Photo of The Countess of Mar The Countess of Mar Deputy Chairman of Committees, Deputy Speaker (Lords)

To ask Her Majesty's Government, further to the Written Answer by Baroness Blackwood of North Oxford on 10 July (HL16834), what steps the Ministry of Defence has taken to address the concerns of the European Medicines Agency Pharmacovigilance Assessment Committee 2014 report on the toxicity of mefloquine (Lariam); and if they have not taken any such steps, why not.

Photo of Earl Howe Earl Howe The Minister of State, Ministry of Defence, Deputy Leader of the House of Lords

Anti-malarial drugs are prescribed to Service personnel with the UK product information leaflet. For mefloquine, this reflects the recommendations of the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency.

All anti-malarial drugs have contraindications and a side effect profile which can be found in the British National Formulary or online at the Electronic Medicines Compendium. It is Ministry of Defence policy that healthcare professionals undertake a health risk assessment and to warn patients of the possible side effects of any anti-malarial drug.

Does this answer the above question?

Yes1 person thinks so

No2 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.